REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference
REGENXBIO Inc. (Nasdaq: RGNX) announced its presentation at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) announced its presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. This virtual conference will showcase the company's advancements in gene therapy. A webcast will be available on REGENXBIO's website, with an archived replay accessible for 30 days. The company utilizes its proprietary NAV Technology Platform to develop innovative gene delivery systems across multiple therapeutic areas.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was +2.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET. The conference will be held in a virtual meeting format.
A webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301203628.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.